Patents Assigned to Xenon Pharmaceuticals
-
Patent number: 11957675Abstract: The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.Type: GrantFiled: February 9, 2022Date of Patent: April 16, 2024Assignee: Xenon Pharmaceuticals Inc.Inventor: Simon Neil Pimstone
-
Patent number: 11325902Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.Type: GrantFiled: July 13, 2020Date of Patent: May 10, 2022Assignee: Xenon Pharmaceuticals Inc.Inventors: Kristen Nicole Burford, Thilo Focken, Verner Alexander Lofstrand, Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 11299490Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.Type: GrantFiled: July 28, 2020Date of Patent: April 12, 2022Assignee: Xenon Pharmaceuticals Inc.Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, James Philip Johnson, Jr., Alla Yurevna Zenova
-
Publication number: 20220064120Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.Type: ApplicationFiled: July 6, 2021Publication date: March 3, 2022Applicant: Xenon Pharmaceuticals Inc.Inventors: Paul Robert BICHLER, Jean-Jacques Alexandre CADIEUX, Matthew David TANDY, Gregory N. BEATCH
-
Publication number: 20220062266Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.Type: ApplicationFiled: October 1, 2021Publication date: March 3, 2022Applicant: Xenon Pharmaceuticals Inc.Inventor: Gregory N. BEATCH
-
Publication number: 20220055977Abstract: The invention provides a method of treating a disease or condition in a mammal by administering a compound having the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein.Type: ApplicationFiled: August 6, 2021Publication date: February 24, 2022Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
-
Patent number: 11203572Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: September 3, 2020Date of Patent: December 21, 2021Assignees: GENENTECH, INC., XENON PHARMACEUTICALS, INCInventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Ivan William Hemeon, Steven McKerrall, Daniel Sutherlin
-
Patent number: 11174268Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.Type: GrantFiled: March 2, 2020Date of Patent: November 16, 2021Assignee: Xenon Pharmaceuticals Inc.Inventors: Jean-Christophe Andrez, David Earl Bogucki, Kristen Nicole Burford, Sultan Chowdhury, Charles Jay Cohen, Shannon Marie Decker, Christoph Martin Dehnhardt, Robert Joseph Devita, James Roy Empfield, Thilo Focken, Michael Edward Grimwood, Syed Abid Hasan, Qi Jia, James Philip Johnson, Jr., Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 11149002Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: December 3, 2019Date of Patent: October 19, 2021Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
-
Patent number: 11135214Abstract: In certain embodiments, the present disclosure is directed to methods and uses for treating seizure disorders in a human, wherein the methods and uses comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof, for example, under fed conditions. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.Type: GrantFiled: May 13, 2019Date of Patent: October 5, 2021Assignee: Xenon Pharmaceuticals Inc.Inventor: Gregory N. Beatch
-
Patent number: 11130726Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: GrantFiled: November 15, 2019Date of Patent: September 28, 2021Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Ivan William Hemeon, Brian Salvatore Safina, Daniel Sutherlin
-
Publication number: 20210253548Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: January 19, 2021Publication date: August 19, 2021Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Chien-an CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Ivan William HEMEON, Steven MCKERRALL, Brian SAFINA, Tao SHENG, Dan SUTHERLIN
-
Patent number: 11091441Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.Type: GrantFiled: October 13, 2020Date of Patent: August 17, 2021Assignee: Xenon Pharmaceuticals Inc.Inventors: Paul Robert Bichler, Jean-Jacques Alexandre Cadieux, Matthew David Tandy, Gregory N. Beatch
-
Publication number: 20210213009Abstract: In certain embodiments, the present disclosure is directed to methods for treating pain in a subject, such as a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the subject in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.Type: ApplicationFiled: December 14, 2020Publication date: July 15, 2021Applicant: Xenon Pharmaceuticals Inc.Inventors: James Philip JOHNSON, JR., Gregory N. BEATCH
-
Publication number: 20210171516Abstract: The invention provides a compound of formula: or a salt thereof, wherein the variables RAA, n, ring A, ring B, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, and R9 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: September 24, 2020Publication date: June 10, 2021Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Philippe BERGERON, Kristen BURFORD, Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Abid HASAN, Kwong Wah LAI, Zhiguo LIU, Steven MCKERRALL, Teresa Phuongtram NGUYEN, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao WANG
-
Publication number: 20210161886Abstract: In certain embodiments, the present disclosure is directed to methods for treating depressive disorders in a human, wherein the methods comprise orally administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A), to the human in need thereof. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.Type: ApplicationFiled: November 9, 2020Publication date: June 3, 2021Applicant: Xenon Pharmaceuticals Inc.Inventors: Cynthia Louise HARDEN, Gregory N. BEATCH
-
Publication number: 20210155588Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: September 3, 2020Publication date: May 27, 2021Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
-
Publication number: 20210147363Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.Type: ApplicationFiled: October 13, 2020Publication date: May 20, 2021Applicant: Xenon Pharmaceuticals Inc.Inventors: Paul Robert BICHLER, Jean-Jacques Alexandre CADIEUX, Matthew David TANDY, Gregory N. BEATCH
-
Patent number: 10981905Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.Type: GrantFiled: August 29, 2019Date of Patent: April 20, 2021Assignee: Xenon Pharmaceuticals Inc.Inventors: Jean-Christophe Andrez, Kristen Nicole Burford, Christoph Martin Dehnhardt, Thilo Focken, Michael Edward Grimwood, Qi Jia, Verner Alexander Lofstrand, Shaoyi Sun, Steven Sigmund Wesolowski, Michael Scott Wilson, Alla Yurevna Zenova
-
Publication number: 20210093618Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.Type: ApplicationFiled: November 7, 2019Publication date: April 1, 2021Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.Inventors: Jean-Christophe ANDREZ, Paul Robert BICHLER, Chien-An CHEN, Sultan CHOWDHURY, Shannon Marie DECKER, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Qi JIA, Jun LI, Zhiguo LIU, Daniel F. ORTWINE, Brian Salvatore SAFINA, Daniel SUTHERLIN, Tao SHENG, Shaoyi SUN, Andrew D. WHITE, Michael Scott WILSON, Alla Yurevna ZENOVA, Jiuxiang ZHU